Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Забрюшинные неорганные саркомы

Список литературы

  1. Bautista N., Su W., O"Connell T.X. Retroperitoneal soft-tissue sarcomas: prognosis and treatment of primary and recurrent disease. Am Surg 2000;66:832–6.
  2. WHO Classification of Tumours of Soft Tissue and Bone 4th edition. Lyon: IARS, 2013.
  3. Trojani M., Contesso G., Coindre J.M. et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a pathological grading system. Int J Cancer 1984;33:37– 42.
  4. Лушников Е.Ф. Лечебный патоморфоз злокачественных новообразований человека. Обнинск, 2016.
  5. Макроскопическое исследование биопсийного и операционного материала: руководство для патологоанатомов. Под ред. Ю.А. Криволапова. М.: Практическая медицина, 2019.
  6. Стилиди И.С., Неред С.Н., Болотский В.И., Огородникова Е.В. Результаты радикальных и паллиативных хирургических вмешательств при забрюшинных неорганных липосаркомах. Паллиативная медицина и реабилитация 2011;(2):9–12.
  7. Стилиди И.С., Никулин М.П., Давыдов М.М. и др. «Нефросохранные» операции в лечении больных неорганными забрюшинными опухолям. Анналы хирургии 2014;(3):47–52.
  8. Стилиди И.С., Цвелодуб С.Б., Матвеев В.Б. и др. Хирургическое лечение больных с лейомиосаркомой нижней полой вены. Анналы хирургии 2013;(5):41–8.
  9. Клименков А.А., Губина Г.И. Неорганные забрюшинные опухоли: основные принципы диагностики и хирургической тактики. Практическая онкология 2004;5(4):285–90.
  10. An J.Y., Heo J.S., Noh J.H. et al. Primary malignant retroperitoneal tumors: analysis of a single institutional experience. Eur J Surg Oncol 2007;33(3):376–82.
  11. Неред С.Н., Стилиди И.С., Клименков А.А. и др. Клинико-морфологические особенности и результаты хирургического лечения забрюшинных неорганных липосарком. Вопросы онкологии 2012;58(1):94–100.
  12. Меликов С.А. Современные методы диагностики и лечения нейрогенных опухолей забрюшинного пространства. Русский медицинский журнал 2012;(2, прил.):47–56.
  13. Бугаев В.Е., Никулин М.П., Меликов С.А. Особенности диагностики и хирургического лечения больных забрюшиными шванномами. Современная онкология 2017;19(4):28–35.
  14. Trans-Atlantic RPS Working Group. Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol 2015;22:256–63.
  15. Цвелодуб С.В., Стилиди И.С. Лейомиосаркома нижней полой вены: обзор литературы. Часть I. Анналы хирургии 2013;1:5–9.
  16. Gronchi A., Strauss D.C., Miceli R. et al. Variability in patterns of recur- rence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS Working Group. Ann Surg 2016;263:1002–9.
  17. Lewis J.J., Leung D., Woodruff J.M., Brennan M.F. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998;228:355–65.
  18. Стилиди И.С., Никулин М.П., Губина Г.И. и др. Опыт хирургического лечения больных с неорганными забрюшинными саркомами с инвазией подвздошных артерий. Анналы хирургии 2012;(6):31–7.
  19. Casali P. G., Abecassis N., Bauer S. et al. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):iv51–67.
  20. Вашакмадзе Л.А., Черемисов В.В., Хомяков В.М. Современные аспекты клиники, диагностики и лечения неорганных опухолей забрюшинного пространства. Онкохирургия 2011;3(1):44–54.
  21. Какиашвили Н.Н. Методы лучевой диагностики в оптимизации диагностической и хирургической тактики при неорганных забрюшинных опухолях. Aвтореф. дис. … канд. мед. наук. М., 2008.
  22. Hull M.A., Niemierko A., Haynes A.B. et al. Post-operative renal function following nephrectomy as part of en bloc resection of retroperitoneal sarcoma (RPS). J Surg Oncol 2015;112:98–102.
  23. Кит О.И., Максимова Н.А., Агаркова Е.И., Ильченко М.Г.. Применение комплексной ультразвуковой диагностики и динамической реносцинтиграфии у пациентов с опухолевым поражением почки в предоперационном периоде при планировании хирургического лечения. Современные проблемы науки и образования 2015;(6):200.
  24. Стилиди И.С., Абгарян М.Г., Калинин А.Е., Бердников С.Н. Хирургическое лечение больных лейомиосаркомой нижней полой вены. Хирургия. Журнал им. Н.И. Пирогова 2017;(10):4– 12.
  25. Стилиди И.С., Абгарян М.Г., Никулин М.П. и др. Ангиопластика в хирургическом лечении больных забрюшинными неорганными саркомами. Хирургия 2017;(5):14–8.
  26. Стилиди И.С., Абгарян М.П., Бохян В.Ю. и др. Резекция и протезирование бифуркации аорты по поводу забрюшинной гломусной опухоли. Онкология. Журнал им. П.А.Герцена 2017;(1):53–6.
  27. Давыдов М.М. Стратегия хирургии внеорганных сарком торакоабдоминальной локализации. Автореф. дис. ... д-ра мед. наук. М., 2015. 48 с.
  28. Бугаев В.Е., Никулин М.П., Петросян А.П. и др. Хирургическое лечение пациентов с забрюшинными шванномами. Вестник РОНЦ 2018;29:9–14.
  29. Gronchi A., Miceli R., Colombo C. et al. Frontline extended surgery is associated with improved survival in retroperitoneal low-tointermediate-grade soft tissue sarcomas. Ann Oncol 2012;23:1067–73.
  30. Bonvalot S., Rivoire M., Castaing M. et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol 2009;27:31–7.
  31. Trans-Atlantic RPS Working Group. Management of primary retroperitoneal sarcoma in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol 2015;22:255–61.
  32. Von Mehren M., Randall R.L., Benjamin R.S. et al. Soft tissue sarcoma, Version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2018;16(5):536–63.
  33. Каприн А.Д., Рябов А.Б., Хомяков В.М. и др. Резекция нижней полой вены при местно- распространенных неорганных забрюшинных опухолях. Онкология. Журнал им. П.А. Герцена 2017;6(1):28–38.
  34. MacNeill A.J., Miceli R., Strauss D.C. et al. Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: a report from the Trans-Atlantic RPS Working Group. Cancer 2017;123:1971–78.
  35. Palassini E., Ferrari S., Verderio P. et al. Feasibility of preoperative chemotherapy with or without radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk in the Italian Sarcoma Group/Grupo Espanol de Investigacion en Sarcomas randomized clinical trial: three versus five cycles of full-dose epirubicin plus ifosfamide. J Clin Oncol 2015;33:3628–34.
  36. Gronchi A., Ferrari S., Quagliuolo V. et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, andomized, controlled, phase 3, andomized trial. Lancet Oncol 2017;18:812–22.
  37. Frustaci S., Gherlinzoni F., De Paoli A. et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238–47.
  38. Lorigan P., Verweij J., Papai Z. et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007;25(21):3144–50.
  39. Patel S.R., Vadhan-Raj S., Papadopolous N. et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies – dose-response and schedule dependence. J Clin Oncol 1997;15(6):2378–84.
  40. Nielsen O.S., Dombernowsky P., Mouridsen H. et al. Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcomas. The experience of the EORTC Soft Tissue and Bone Sarcoma Group. Sarcoma 2000;4(1–2):31–5.
  41. Zalupski M., Metch B., Balcerzak S. et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusionin patients with soft-tissue sarcomas: a Southwest Oncology Group Study. J Natl Cancer Inst 1991;83(13):926–32.
  42. Hensley M.L., Maki R., Venkatraman E. et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: resultsof a phase II trial. J Clin Oncol 2002;20(12):2824–31.
  43. Judson I., Verweij J., Gelderblom H. et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014;15(4):415–23.
  44. Worden F.P., Taylor J.M.G., Biermann J.S. et al. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 2005;23(1):105–12.
  45. Noujaim J., Constantinidou A., Messiou C. et al. Successful ifosfamide rechallenge in soft-tissue sarcoma. Am J Clin Oncol 2015;41(2);147–51.
  46. Seddon B.M., Whelan J., Strauss S.J. et al. GeDDiS: a prospective random controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009- 014907-29). J Clin Oncol 2015;33(Suppl 15):10500.
  47. Van der Graaf W.T., Blay J.Y., Chawla S.P. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind, placebo- controlled phase 3 trial. Lancet 2012;379:1879–86.
  48. Le Cesne A., Antoine E., Spielmann M. et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600–8.
  49. Martin-Liberal J., Alam S., Constantinidou A. et al. Clinical activity and tolerability of a 14-day infusional ifosfamide schedule in soft-tissue sarcoma. Sarcoma 2013;2013:868973.
  50. Demetri G.D., Chawla S.P., von Mehren M. et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27:4188–96.
  51. Demetri G.D., von Mehren M., Jones R.L. et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 2016;34:786–93.
  52. Maki R.G., Wathen J.K., Patel S.R. et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007;25:2755–63.
  53. García-Del-Muro X., López-Pousa A., Maurel J. et al.; Spanish Group for Research on Sarcomas. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011;29(18):2528–33.
  54. Dickson M.A., Schwartz G.K., Keohan M.L. et al. Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial. JAMA Oncol 2016;2(7):937–40.
  55. Penel N., Bui B.N., Bay J.-O. et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008;26(32):5269–74.
  56. Stacchiotti S., Palassini E., Sanfilippo R. et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol 2012;23(2):501–8.
  57. Wagner A.J., Malinowska-Kolodziej I., Morgan J.A. et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010;28(5):835–40.
  58. Переводчикова Н.И. Руководство по химиотерапии опухолевых заболеваний. 2-е изд., доп. и перераб. М., 2005.
  59. Benjamin R.S., Wiernik P.H., Bachur N.R. Adriamycin: a new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol 1975;1(1):63–76.
  60. Borden E.C., Amato D.A., Rosenbaum C. et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987;5(6):840–50.
  61. Schoffski P., Chawla S., Maki R.G. et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016;387:1629–37.
  62. Gennatas C., Michalaki V., Kairi P.V. et al. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor. World J Surg Oncol 2012;10:181.
  63. Treatment guidelines for preoperative radiation therapy for retroperitoneal sarcoma: preliminary consensus of an international expert panel. Int J Radiation Oncol Biol Phys 2015;92(3):602–12.
  64. Baldini E.H., Bosch W., Kane J.M. 3rd et al. Retroperitoneal sarcoma (RPS) high risk gross tumor volume boost (HR GTV boost) contour delineation agreement among NRG sarcoma radiation and surgical oncologists. Ann Surg Oncol 2015;22:2846–52.
  65. Tuan J., Vitolo V., Vischioni B. et al. Radiation therapy for retroperitoneal sarcoma. Radiol Med 2014;119(10):790–802.
  66. Cosper P., Olsen J., De Wees T. et al. Intensity-modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institute experience. Radial Oncol 2017;12:198.
  67. Tzeng C.W., Fiveash J.B., Popple R.A. et al. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. Cancer 2006;107:371–9.
  68. Musat E., Kantor G., Caron J. et al. Comparison of intensity-modulated postoperative radiotherapy with conventional postoperative radiotherapy for retroperitoneal sarcoma. Cancer Radiother 2004;8:255–61.
  69. Swanson E.L., Indelicato D.J., Louis D. et al. Comparison of three-dimensional (3D) conformal proton radiotherapy (RT), 3D conformal photon RT, and intensity-modulated RT for retroperitoneal and intra-abdominal sarcomas. Int J Radiat Oncol Biol Phys 2012;83(5):1549–57.
  70. Silver J.K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013;92(8):715–27.
  71. Nilsson H., Angeras U., Bock D. et al. Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer. BMJ Open 2016;6(1):e007997.
  72. Siegel G.W., Biermann J.S., Chugh R. et al. The multidisciplinary management of bone and soft tissue sarcoma: an essential organizational framework. J Multidiscip Healthc 2015;8:109–15.
  73. The diagnosis and treatment of lymphedema. Position Statement of the National Lymphedema Network Committee. NMA 2011:1–19.
  74. Segal R., Zwaal C., Green E. et al. Exercise for people with cancer: a systematic review. Curr Oncol 2017;24(4):e290–315.
  75. Boyd C., Crawford C., Paat C.F. et al. the impact of massage therapy on function in pain populations-a systematic review and meta-analysis of randomized controlled trials: Part II, cancer pain populations. Pain Med 2016;17(8):1553–68.
  76. Stout N.L., Baima J., Swisher A.K. et al. A systematic review of exercise systematic reviews in the cancer literature (2005–2017). PM R 2017;9(9S2):S347–84.
  77. Hu M., Lin W. Effects of exercise training on red blood cell production: implications for anemia. Acta Haematol 2012;127(3):156–64.
  78. Bland K.A., Zadravec K., Landry T. et al. Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research. Crit Rev Oncol Hematol 2019;136:79–85.
  79. Mustian K.M., Alfano C.M., Heckler C. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017;3(7):961–8.
  80. Kessels E., Husson O., van der Feltz-Cornelis C.M. The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. Neuropsychiatr Dis Treat 2018;14:479–94.
  81. Devine D., Parker P.A., Fouladi R.T., Cohen L. The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment. Psychooncology 2003;12(5):453–62.
  82. Беляев А.М., Чулкова В.А., Семиглазова Т.Ю., Рогачев М.В. Онкопсихология для врачей- онкологов и медицинских психологов. Руководство. СПб.: Любавич, 2017.
  83. Gamboa A.C., Ethun C.G, Switchenko J. M et al. Lung surveillance strategy for high-grade soft tissue sarcomas: chest X-rayor CT scan? J Am Coll Surg 2019;229(5):449–57.
  84. Edmonson J.H., Ryan L.M., Blum R.H. et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269–75.
  85. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350:1647–54.
  86. Рervaiz N., Colterjohn N., Farrokhyar F. et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113:573–81.
  87. Edmonson J., Ryan L., Blum R. et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269–75.
  88. Benjamin R.S., Legha S.S., Patel S.R., Nicaise C. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol 1993;31(Suppl 2):S174–9.
  89. Le Cesne A., Antoine E., Spielmann M. et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600–8.
  90. Горбунова В.А., Феденко А.А., Истомин И.А. и др. Высокодозный ифосфамид в комбинации с доксорубицином в лечении сарком мягких тканей. Саркомы костей, мягких тканей и опухоли кожи 2010;(1):26–31.
  91. Ravi V., Patel S., Benjamin R.S. Chemotherapy for soft-tissue sarcomas. Oncology (Williston Park) 2015;29(1):43–50.
  92. Trans-Atlantic RPS Working Group. Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol 2015;22(1):256e63.
  93. Grobmyer S.R., Wilson J.P., Apel B. et al. Recurrent retroperitoneal sarcoma: impact of biology and therapy on outcomes. J Am Coll Surg 2010;210:602–8.
  94. Gronchi A., Miceli R., Allard M.A. et al. Personalizing the approach to retroperitoneal soft tissue sarcoma: histology-specific patterns of failure and post-relapse outcome after primary extended resection. Ann Surg Oncol 2015;22(5):1447–54.
  95. Pervaiz N., Colterjohn N., Farrokhyar F. et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113:573–81.
  96. Woll P.J., Reichardt P., Le Cesne A. et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft- tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012;13:1045–54.
  97. Ahlen J., Ahuja N., Albertsmeier M. Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Oncol 2018;29:857–71.
  98. Schöffski P., Ray-Coquard I.L., Cioffi A. et al. Activity of eribulin mesylate in patients with soft- tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncology 2011;12(11):1045–52.
  99. Chawla S. Subtype specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open label, randomised study of eribulin (ERI) versus dacarbazine (DTIC) in patients with advanced LPS and leiomyosarcoma (LMS). In: American Society for Clinical Oncology Annual Meeting 2016; Abstract 11037.
  100. Gennatas C., Michalaki V., Kairi P.V. et al. Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor World J Surg Oncol 2012;10:181.
  101. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents. Ed. by C. MacLeod New York: Columbia University Press, 1949. Pp. 191–205.
  102. Oken M.M., Creech R.H., Tormey D.C. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649–55.
  103. NCCN Guidelines Version 2.2020. Soft Tissue Sarcoma.
  104. Datta J., Ecker B.L., Neuwirth M.G. et al. Contemporary reappraisal of the efficacy of adjuvant chemotherapy in resected retroperitoneal sarcoma: evidence from a nationwide clinical oncology database and review of the literature. Surg Oncol 2017;26(2):117–24.
  105. Miura J.T., Charlson J., Gamblin T.C. et al. Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma. Eur J Surg Oncol 2015;41(10):1386–92.
  106. Pervaiz N., Colterjohn N., Farrokhyar F. et al. A systematic metaanalysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113:573–81.
  107. Bremjit P.J., Jones R.L., Chai X. et al. A contemporary large single‐institution evaluation of resected retroperitoneal sarcoma. Ann Surg Oncol 2013;21:2150–8.
  108. Davis E.J., Chugh R., Zhao L. et al. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high- risk, soft tissue sarcoma. Eur J Cancer 2015;51(13):1794–802.
  109. Stacchiotti S., Grosso F., Negri T. et al. Tumor response to sunitinib malate observed in clear-cell sarcoma. Ann Oncol 2010;21:1130–1.
  110. Mir O., Boudou-Rouquette P., Larousserie F. et al. Objective response to sorafenib in advanced clear-cell sarcoma. Ann Oncol 2012;23:807–9.
  111. Martin-Broto J., Pousa A.L., de Las Penas R. et al. Randomized phase ii study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: a Spanish Group for Research on Sarcoma Study. J Clin Oncol 2016;34:2294–302.
  112. D"Ambrosio L., Touati N., Blay J.Y. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer 2020;126(11):2637–47.
  113. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO/European Sarcoma Network Working Group. Ann Oncol 2014;25 Suppl 3:iii102–12.
  114. Pervaiz N., Colterjohn N., Farrokhyar F. et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113(3):573–81.
  115. Van Winkle P., Angiolillo A., Krailo M. et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children"s Cancer Group (CCG) experience. Pediatr Blood Cancer 2005;44(4):338–47.
  116. Minchom A., Jones R.L., Fisher S. et al. Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Sarcoma 2010;2010:264360.
  117. Lee S.H., Chang M.H., Baek K.K. et al. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. Oncology 2011;80(3–4):257– 61.
  118. Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И. Переводчиковой. 2- е изд., доп. М.: Практическая медицина, 2005. 661 с.
  119. Гележе П.В., Морозов С.П., Мандельблат Ю.Э., Либсон Е.И. Современные критерии лучевой диагностики в оценке эффективности специального противоопухолевого лечения. Российский онкологический журнал 2014;(3):39–45.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*